Table 2: Univariate cox-regression analysis of event free survival and overall survival in the total ALL patient group


 

EFS

OS


 

n(%)

HR

(95% CI)

p value

HR

95%CI

p value


Sex

 

 

 

 

 

 

 

 Female

86(41)

1

 

 

1

 

 

 Male

125(59)

1.5

0.92 – 2.38

0.11

0.65

0.41 – 1.04

0.07

Age at diagnosis

 

 

 

 

 

 

 

 1 – 9 years

165(78)

1

 

 

1

 

 

<1 and  >10 years

46(22)

1.9

1.14 – 3.30

0.01

1.67

0.99 – 2.84

0.06

WBC at diagnosis

 

 

 

 

 

 

 

< 50.000/mm3

169(80)

1

 

 

1

 

 

> 50.000/mm3

42(20)

1.5

0.82 – 2.66

0.19

1.47

0.83 – 2.61

0.18

Classification*

 

 

 

 

 

 

 

 Standard Risk

94(45)

1

 

 

1

 

 

 High Risk

117(55)

2.2

1.22 – 4.02

0.01

1.86

1.06 – 3.26

0.03

FAB

 

 

 

 

 

 

 

 ALL-L1

175(83)

1

 

 

1

 

 

 ALL-L2

36(17)

1.2

0.64 – 2.09

0.63

0.82

0.43 – 1.57

0.55

Immunophenotyping

 

 

 

 

 

 

 

 B-lineage ALL

178(84)

1

 

 

1

 

 

 T-lineage ALL

33(16)

1.4

0.75 – 2.50

0.31

1.45

0.82 – 2.56

0.20

CD10 expression

 

 

 

 

 

 

 

 CD10+

148(70)

1

 

 

1

 

 

 CD10-

63(30)

1.9

1.19 – 3.15

0.01

2.13

1.33 – 3.41

0.002

CD34 expression

 

 

 

 

 

 

 

 CD34+

112(53)

1

 

 

1

 

 

CD34-

99(47)

1.1

0.72 – 1.89

0.52

1.25

0.78 – 2.00

0.36

Combination CD10 and CD34

 

 

 

 

 

 

 

 CD10+CD34+

84(40)

1

 

 

1

 

 

 CD10+CD34-

64(30)

0.9

0.47 – 1.67

0.71

0.91

0.48 – 1.72

0.78

 CD10-CD34+

28(13)

1.4

0.66 – 2.95

0.39

1.43

0.67 – 3.03

0.36

 CD10-CD34-

35(17)

2.2

1.18 – 4.15

0.01

2.81

1.56 – 5.07

0.001

CD10- and CD34-

 

 

 

 

 

 

 

 CD10+ and/or CD34+

176(83)

1

 

 

1

 

 

 CD10-CD34-

35(17)

2.2

1.27 – 3.75

0.01

2.73

1.65 – 4.53

<0.001


 

Supriyadi et al.Journal of Cancer Therapeutics and Research  2012 1:20DOI : 10.7243/2049-7962-1-20